A detailed history of Royce & Associates LP transactions in Alvotech stock. As of the latest transaction made, Royce & Associates LP holds 131,000 shares of ALVO stock, worth $1.65 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
131,000
Previous 94,000 39.36%
Holding current value
$1.65 Million
Previous $1.14 Million 36.31%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$10.76 - $12.99 $398,120 - $480,630
37,000 Added 39.36%
131,000 $1.56 Million
Q2 2024

Aug 13, 2024

BUY
$11.4 - $14.51 $1.07 Million - $1.36 Million
94,000 New
94,000 $1.14 Million

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $3.12B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.